Targeting fundamental aging mechanisms to treat osteoporosis

被引:18
作者
Feehan, Jack [1 ,2 ]
Al Saedi, Ahmed [1 ,2 ]
Duque, Gustavo [1 ,2 ]
机构
[1] Univ Melbourne & Western Hlth, Australian Inst Musculoskeletal Sci AIMSS, 176 Furlong Rd, St Albans 3021, Australia
[2] Univ Melbourne, Melbourne Med Sch, Dept Med Western Hlth, St Albans, Australia
关键词
Osteoporosis; Anabolics; aging; kynurenines; Wnts; RANKL; Sclerostin; Osteosarcopenia; Antiresorptives;
D O I
10.1080/14728222.2019.1702973
中图分类号
R9 [药学];
学科分类号
100702 [药剂学];
摘要
Introduction: Osteoporotic fractures represent a growing burden of mortality, morbidity and socioeconomic cost to health-care systems worldwide. Osteoporosis is a disease uniquely associated with aging, therefore, an understanding of the physiological mechanisms underpinning its development as we age may open new avenues for therapeutic exploitation. Novel treatments, as well as refinement of the current approaches, are vital in the effort to sustain healthy, independent patients across the lifespan. Areas covered: This review covers the anabolic and catabolic pathways seen in bone maintenance, highlighting how they are changed with age, leading to osteoporosis. It will also discuss how these changes may be targeted therapeutically, in the development of new therapies, and the refinement of those already in use. Expert opinion: New effective and safe treatments for osteoporosis are still needed. Bone anabolics seem to be the most appropriate therapeutic approach to osteoporosis in older persons. Considering that bone and muscle mass synchronically decline with aging thus predisposing older persons to falls and fractures, combined therapeutic approaches to osteosarcopenia with a dual anabolic effect on muscle and bone will be a major advance in the treatment of these devastating conditions in the future.
引用
收藏
页码:1031 / 1039
页数:9
相关论文
共 104 条
[1]
Al Saedi A., 2019, J. Lab. Precis. Med., V4, P7, DOI 10.21037/jlpm.2019.02.01
[2]
Arun Banu, 2002, Expert Opin Pharmacother, V3, P681
[3]
Indoleamine 2,3-dioxygenase expression is restricted to fetal trophoblast giant cells during murine gestation and is maternal genome specific [J].
Baban, B ;
Chandler, P ;
McCool, D ;
Marshall, B ;
Munn, DH ;
Mellor, AL .
JOURNAL OF REPRODUCTIVE IMMUNOLOGY, 2004, 61 (02) :67-77
[4]
STIMULATION OF OSTEOCLASTIC BONE-RESORPTION BY HYDROGEN-PEROXIDE [J].
BAX, BE ;
ALAM, ASMT ;
BANERJI, B ;
BAX, CMR ;
BEVIS, PJR ;
STEVENS, CR ;
MOONGA, BS ;
BLAKE, DR ;
ZAIDI, M .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1992, 183 (03) :1153-1158
[5]
Treatment with an inhibitor of fatty acid synthase attenuates bone loss in ovariectomized mice [J].
Bermeo, Sandra ;
Al Saedi, Ahmed ;
Vidal, Christopher ;
Khalil, Mamdouh ;
Pang, Manhui ;
Troen, Bruce R. ;
Myers, Damian ;
Duque, Gustavo .
BONE, 2019, 122 :114-122
[6]
Dual effect of strontium ranelate:: Stimulation of osteoblast differentiation and inhibition of osteoclast formation and resorption in vitro [J].
Bonnelye, Edith ;
Chabadel, Anne ;
Saltel, Frederic ;
Jurdic, Pierre .
BONE, 2008, 42 (01) :129-138
[7]
High bone density due to a mutation in LDL-receptor-related protein 5 [J].
Boyden, LM ;
Mao, JH ;
Belsky, J ;
Mitzner, L ;
Farhi, A ;
Mitnick, MA ;
Wu, DQ ;
Insogna, K ;
Lifton, RP .
NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (20) :1513-1521
[8]
T Cell Costimulation Molecules CD80/86 Inhibit Osteoclast Differentiation by Inducing the IDO/Tryptophan Pathway [J].
Bozec, Aline ;
Zaiss, Mario M. ;
Kagwiria, Rosebeth ;
Voll, Reinhard ;
Rauh, Manfred ;
Chen, Zhu ;
Mueller-Schmucker, Sandra ;
Kroczek, Richard A. ;
Heinzerling, Lucie ;
Moser, Muriel ;
Mellor, Andrew L. ;
David, Jean-Pierre ;
Schett, Georg .
SCIENCE TRANSLATIONAL MEDICINE, 2014, 6 (235)
[9]
Calvo A., 2018, J CLIN ONCOL, V36, P3014
[10]
Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy [J].
Cannarile, Michael A. ;
Weisser, Martin ;
Jacob, Wolfgang ;
Jegg, Anna-Maria ;
Ries, Carola H. ;
Ruettinger, Dominik .
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2017, 5